Monograph
H03BA02 - Propylthiouracil |
Propably not porphyrinogenic |
PNP |
Rationale
Propylthiouracil is not metabolized by cyp-enzymes, nor does it induce or inhibit the activity of cyp-enzymes. Propylthiouracil has no potential porphyrogenic pharmacokinetic or pharmacodynamic properties.
Chemical description
Propylthiouracil is a thiourea anti thyroid drug. It inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine.
Therapeutic characteristics
Propylthiouracil is used in the management of hyperthyroidism. It is usually administered orally.
Metabolism and pharmacokinetics
Propylthiouracil undergoes rapid first-pass metabolism in the liver, and is mainly excreted in the urine as the glucuronic acid conjugate, with very little excreted as unchanged drug. It has an elimination half-life of 1-3 hours. Propylthiouracil is about 80% bound to plasma proteins. Propylthiouracil has no potential of pharmacokinetic drug interactions involving cyp-enzymes.
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Drug reference publications | |
| 1. | DrugBank. Propylthiouracil.
|
|
| 2. | Sweetman SC, editor. Martindale: The complete drug reference. Propylthiouracil
|
|
| * | Summary of Product Characteristics | |
| 3. | Swedish medicines agency. Summary of Product Characteristics (SPC) Tiotil. (05.09.2011).
|
|
Tradenames
Propylthiouracil 
Propylthiouracile 
Propycil 
Propycil 
Propylthiouracil 
Propyltiouracil 
Propyltiouracil 
Propycil · Thyrosan 
Propylthiouracile 
Tiotil 
ptu 
Propiltiouracil · Propiltiouracil Alakloid 
Propacil · Propylthiouracil · Prothyran · Thyreostat 
Propylthiouracile 
Propiltiouracilo 
Propylthiouracil